Current Treatment Options in Gastroenterology

, Volume 7, Issue 6, pp 423–430

Nonalcoholic steatohepatitis

  • Brian P. Mulhall
  • Zobair M. Younossi
Article

DOI: 10.1007/s11938-004-0001-9

Cite this article as:
Mulhall, B.P. & Younossi, Z.M. Curr Treat Options Gastro (2004) 7: 423. doi:10.1007/s11938-004-0001-9

Opinion statement

Nonalcoholic steatohepatitis (NASH) is an important medical condition and there is great public health concern related to its increasing incidence and potential implications for the development of end-stage liver disease. NASH represents a progression beyond simple lipid deposition in the liver parenchyma, requiring histologic evidence for hepatocyte injury such as ballooning degeneration, Mallory bodies, and/or pericellular fibrosis that can potentially lead to progressive liver injury and eventually cirrhosis. It is believed that several insults contribute to the evolution of hepatic injury such as insulin dysregulation, lipid deposition, oxidative free radicals, and lipid perioxidation. Initial treatment protocols for NASH focus on various aspects of injury in an attempt to control insulin imbalances, improve lipid regulation, reduce free radicals, and ameliorate the inflammatory process. No therapy is conclusively beneficial in all individuals, but preliminary data suggest several approaches that hold promise.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Brian P. Mulhall
    • 1
  • Zobair M. Younossi
    • 1
  1. 1.Center for Liver Diseases, Department of MedicineInova Fairfax HospitalFalls ChurchUSA

Personalised recommendations